Compare Novavax Inc (NVAX) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs iShares Semiconductor ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while iShares Semiconductor ETF trades at $559.4 (market cap $48.19B). The key difference: iShares Semiconductor ETF is far larger — about 26.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and iShares Semiconductor ETF for 46 Days on average.
| NVAX | SOXX | |
|---|---|---|
Market Cap | $1.82B | $48.19B |
Volume | 6,198,505 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $12.56 | $655.01 |
52-Week Low | $6.22 | $268.10 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
SOXX trades at $559.40, down 4.04% over the past 24 hours amid broader semiconductor sector volatility. The ETF maintains a bullish technical signal with strong moving average support, while oscillators show neutral momentum. Recent news highlights continued AI-driven semiconductor demand with projections of market growth to $2.3 trillion by 2030, though concerns about valuation premiums and Michael Burry's expanded short positions create mixed sentiment.
The semiconductor sector faces a critical juncture with AI infrastructure demand driving earnings growth while elevated valuations present headwinds. SOXX's fundamental strength depends on continued chip industry expansion, though concentration risk and potential market rotation pose significant challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
